NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Applovin
APP
US Stock MarketDetailed Quotes
ATHA Athira
- 0.439
- +0.049+12.51%
Close Feb 26 16:00 ET
16.98MMarket Cap-0.15P/E (TTM)
0.480High0.390Low470.37KVolume0.390Open0.390Pre Close208.61KTurnover1.73%Turnover RatioLossP/E (Static)38.67MShares4.21052wk High0.29P/B11.94MFloat Cap0.36852wk Low--Dividend TTM27.19MShs Float34.790Historical High--Div YieldTTM23.07%Amplitude0.368Historical Low0.443Avg Price1Lot Size
About Athira Company
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Company Profile
SymbolATHA
Company NameAthira
Listing DateSep 18, 2020
Issue Price17.00
Founded2011
CEODr. Mark J. Litton, PhD
MarketNASDAQ
Employees67
Fiscal Year Ends12-31
Address18706 North Creek Parkway,Suite 104
CityBothell
ProvinceWashington
CountryUnited States of America
Zip Code98011
Phone1-425-620-8501
Websitehttp://www.athira.com
Company Executives
- Name
- Position
- Salary
- Dr. Mark J. Litton, PhD
- Director, President and Chief Executive Officer
- 2.26M
- Dr. Kevin Church, PhD
- Chief Scientific Officer
- --
- Robert Renninger
- Principal Financial Officer, Principal Accounting Officer and Vice President, Finance
- --
- Barbara Kosacz, J.D.
- Independent Director
- 102.39K
- Joseph Edelman
- Independent Director
- 92.77K
- John M. Fluke, Jr
- Independent Director
- 95.89K
- James A. Johnson
- Independent Director
- 106.87K
- Grant E. Pickering
- Independent Director
- 96.53K
- Dr. Michael A. Panzara, M.D.
- Independent Director
- 89.36K
- Mark Worthington
- General Counsel and Corporate Secretary
- --
- Kelly A. Romano
- Chairwoman of the Board
- 124.68K